Início › Leucemia Linfocítica Crônica › Oregon
Ensaios clínicos de Leucemia Linfocítica Crônica em Oregon
17 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Oregon.
Cidades em Oregon
Texto oficial do estudo (Inglês)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Oregon Health and Science University ( Site 5425), Portland
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05947851Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06784167A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Portland
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06564038Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- e mais 3
RecrutandoFase 3
Idades 65 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- e mais 8
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT05334069Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Oncology Associates of Oregon, Eugene
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07520006Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
RecrutandoFase 1/2
Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579A Long-term Extension Study of PCI-32765 (Ibrutinib)
- Willamette Valley Cancer Center, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 31 de jul. de 2026 · NCT01804686A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Williamette Valley Cancer Institute & Research Center, Eugene
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de mai. de 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- OHSU Knight Cancer Institute, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 6 de nov. de 2025 · NCT05943496A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.